Santhera Presents Clinical Data of Catena® in Duchenne Muscular Dystrophy at the 2011 Congress of the World Muscle Society
Santhera Pharmaceuticals Holding AG /
Santhera Presents Clinical Data of Catena® in Duchenne Muscular Dystrophy at the
2011 Congress of the World Muscle Society
. Verarbeitet und übermittelt durch Thomson Reuters ONE.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Liestal, Switzerland, October 19, 2011 - Santhera Pharmaceuticals (SIX: SANN)
announced today that it will present data from the 2-year open-label study
(DELPHI-E study) evaluating Catena® for the treatment of Duchenne Muscular
Dystrophy [1], one of the most common and devastating types of muscular
dystrophy. The findings indicate that Catena® slowed the decline in respiratory
function compared to the expected natural history in patients with Duchenne
Muscular Dystrophy. Data from this study are in agreement with and confirm data
from a randomized controlled study (DELPHI study) of 12 months duration [2]. The
poster presentation will be given at the 16th International Congress of the
World Muscle Society in Almancil, Portugal on October 21, 2011.
References
[1] Buyse G.M., Goemans N., van den Hauwe M., Thijs D., Wei Hui, Rummey C.,
Meier T., Mertens L.: Results from a two-year open label intervention study with
idebenone (Catena®) in patients with Duchene Muscular Dystrophy. Poster
presentation at the 16th International Congress of the World Muscle Society in
Almancil, Portugal, from October 18 to 22, 2011.
[2] Buyse G.M., Goemans N., van den Hauwe M., Thijs D., de Groot ( )I.J.M.,
Schara U., Ceulemans B., Meier T., Mertens M.: Idebenone as a novel, therapeutic
approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind,
randomized placebo-controlled trial. Neuromuscular Disorders 2011; 21:396-405.
About Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy is the most common and a devastating type of
muscular degeneration and results in rapidly progressive muscle weakness. It is
a genetic, degenerative disease that is inherited in an X-linked recessive mode.
Duchenne Muscular Dystrophy affects approximately 30,000 patients in the USA,
EU, and Japan and its incidence is approximately 1 in 3,500 live born males
worldwide. Duchenne Muscular Dystrophy is characterized by a loss of the protein
dystrophin, leading to progressive muscle weakness and wasting through a complex
cascade that involves impaired calcium homeostasis, mitochondrial dysfunction
and oxidative stress. The average age of onset is between 3 and 5 years of age
with a loss of ambulation in teenage patients. Dilated cardiomyopathy and
respiratory failure are commonly associated with this chronic disease leading to
early morbidity and mortality in Duchenne Muscular Dystrophy patients.
* * *
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company
focused on the development and commercialization of innovative pharmaceutical
products for the treatment of severe neuromuscular diseases, an area of high
unmet medical need which includes many orphan indications with no current
therapy. Santhera's first product, Catena®, to treat Friedreich's Ataxia is
marketed in Canada. Catena® is currently under review for marketing
authorization by the European Medicine Agency as the first therapy for patients
suffering from Leber's Hereditary Optic Neuropathy. For further information,
please visit www.santhera.com.
Catena® is a trademark of Santhera Pharmaceuticals.
For further information, contact
Thomas Meier, Chief Executive Officer
Phone: +41 (0)61 906 89 64
thomas.meier@santhera.com
Thomas Staffelbach, Head Public & Investor Relations
Phone: +41 (0)61 906 89 47
thomas.staffelbach@santhera.com
Disclaimer/Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from those
expressed or implied by such statements. Readers should therefore not place
undue reliance on these statements, particularly not in connection with any
contract or investment decision. The Company disclaims any obligation to update
these forward-looking statements.
--- Ende der Mitteilung ---
Santhera Pharmaceuticals Holding AG
Hammerstrasse 49 Liestal Schweiz
ISIN: CH0027148649;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via Thomson Reuters ONE
[HUG#1555625]
http://www.santhera.com
Santhera Pharmaceuticals Holding AG /
Santhera Presents Clinical Data of Catena® in Duchenne Muscular Dystrophy at the
2011 Congress of the World Muscle Society
. Verarbeitet und übermittelt durch Thomson Reuters ONE.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Liestal, Switzerland, October 19, 2011 - Santhera Pharmaceuticals (SIX: SANN)
announced today that it will present data from the 2-year open-label study
(DELPHI-E study) evaluating Catena® for the treatment of Duchenne Muscular
Dystrophy [1], one of the most common and devastating types of muscular
dystrophy. The findings indicate that Catena® slowed the decline in respiratory
function compared to the expected natural history in patients with Duchenne
Muscular Dystrophy. Data from this study are in agreement with and confirm data
from a randomized controlled study (DELPHI study) of 12 months duration [2]. The
poster presentation will be given at the 16th International Congress of the
World Muscle Society in Almancil, Portugal on October 21, 2011.
References
[1] Buyse G.M., Goemans N., van den Hauwe M., Thijs D., Wei Hui, Rummey C.,
Meier T., Mertens L.: Results from a two-year open label intervention study with
idebenone (Catena®) in patients with Duchene Muscular Dystrophy. Poster
presentation at the 16th International Congress of the World Muscle Society in
Almancil, Portugal, from October 18 to 22, 2011.
[2] Buyse G.M., Goemans N., van den Hauwe M., Thijs D., de Groot ( )I.J.M.,
Schara U., Ceulemans B., Meier T., Mertens M.: Idebenone as a novel, therapeutic
approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind,
randomized placebo-controlled trial. Neuromuscular Disorders 2011; 21:396-405.
About Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy is the most common and a devastating type of
muscular degeneration and results in rapidly progressive muscle weakness. It is
a genetic, degenerative disease that is inherited in an X-linked recessive mode.
Duchenne Muscular Dystrophy affects approximately 30,000 patients in the USA,
EU, and Japan and its incidence is approximately 1 in 3,500 live born males
worldwide. Duchenne Muscular Dystrophy is characterized by a loss of the protein
dystrophin, leading to progressive muscle weakness and wasting through a complex
cascade that involves impaired calcium homeostasis, mitochondrial dysfunction
and oxidative stress. The average age of onset is between 3 and 5 years of age
with a loss of ambulation in teenage patients. Dilated cardiomyopathy and
respiratory failure are commonly associated with this chronic disease leading to
early morbidity and mortality in Duchenne Muscular Dystrophy patients.
* * *
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company
focused on the development and commercialization of innovative pharmaceutical
products for the treatment of severe neuromuscular diseases, an area of high
unmet medical need which includes many orphan indications with no current
therapy. Santhera's first product, Catena®, to treat Friedreich's Ataxia is
marketed in Canada. Catena® is currently under review for marketing
authorization by the European Medicine Agency as the first therapy for patients
suffering from Leber's Hereditary Optic Neuropathy. For further information,
please visit www.santhera.com.
Catena® is a trademark of Santhera Pharmaceuticals.
For further information, contact
Thomas Meier, Chief Executive Officer
Phone: +41 (0)61 906 89 64
thomas.meier@santhera.com
Thomas Staffelbach, Head Public & Investor Relations
Phone: +41 (0)61 906 89 47
thomas.staffelbach@santhera.com
Disclaimer/Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from those
expressed or implied by such statements. Readers should therefore not place
undue reliance on these statements, particularly not in connection with any
contract or investment decision. The Company disclaims any obligation to update
these forward-looking statements.
--- Ende der Mitteilung ---
Santhera Pharmaceuticals Holding AG
Hammerstrasse 49 Liestal Schweiz
ISIN: CH0027148649;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via Thomson Reuters ONE
[HUG#1555625]
http://www.santhera.com